ArticleDiscover oncology2026
Exosomal circVANGL1 promotes cisplatin resistance in osteosarcoma cells by regulating the miR-145-5p/E2F3 axis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectivesOsteosarcoma (OS) is a malignant bone tumor originating directly from bone tissue, predominantly affecting adolescents. Cisplatin (DDP)-based chemotherapy is commonly used in the treatment of OS, but the emergence of DDP resistance poses a significant challenge to effective management. The study aimed to investigate the role of circRNA VANGL1 (circVANGL1) in mediating DDP resistance in OS in vitro. MATERIALS AND
methodsThe OS cell lines U2OS and MG-63 were used, and DDP-resistant cell models (U2OS-DR and MG-63-DR) were established. Transfection with circVANGL1 siRNA was performed to silence circVANGL1 expression, and its impact on cell proliferation, apoptosis, DDP resistance, and miR-145-5p level was studied. Fluorescence in situ hybridization was employed to localize circVANGL1. TargetScan prediction was utilized to identify the interaction between circVANGL1 and miR-145-5p. Co-transfection experiments of si-circVANGL1 with anti-miR-145-5p or E2F3 overexpression vector (E2F3-oe) were conducted to assess their effects on DDP-resistant cells.
resultsCompared to the parental cells, the expression of circVANGL1 was increased by approximately 2.2-fold and 2.5-fold in U2OS-DR and MG-63-DR cells, respectively (P < 0.01). Transfection with si-circVANGL1 effectively suppressed cell proliferation and DDP resistance while promoting apoptosis in DDP-resistant cells. circVANGL1 is transferred via exosomes and primarily localized in the cytoplasm of U2OS and MG-63 cells. TargetScan prediction indicated a target relationship between circVANGL1 and miR-145-5p. Co-transfection of si-circVANGL1 with anti-miR-145-5p or E2F3-oe counteracted the changes in proliferation and apoptosis observed with si-circVANGL1 transfection alone in DDP-resistant cells.
conclusionIn vitro findings preliminarily suggest that exosomal circVANGL1 may promote DDP resistance in OS cells by regulating the miR-145-5p/E2F3 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.